SHR2554 + SHR3680

**SHR2554 + SHR3680** is an investigational combination of two small-molecule oral agents under clinical development for advanced cancer indications, primarily metastatic castration-resistant prostate cancer (mCRPC). - **SHR2554** is an oral inhibitor of **Enhancer of zeste homolog 2 (EZH2)**, an epigenetic regulator implicated in tumorigenesis[2][3][5]. - **SHR3680** is an oral **androgen receptor (AR) inhibitor**, designed to block androgen-receptor driven signaling in prostate cancer[1][4]. The combination harnesses the antitumor activity of both targeted epigenetic modulation (EZH2 inhibition) and hormone axis interference (AR inhibition). Clinical trials evaluate its pharmacokinetics, safety, and efficacy in mCRPC and other advanced solid tumors, and it is also considered for AR-positive advanced breast cancer[1][4].